Literature DB >> 31601698

Preoperative Localization of Adenomas in Primary Hyperparathyroidism: The Value of 11C-Choline PET/CT in Patients with Negative or Discordant Findings on Ultrasonography and 99mTc-Sestamibi SPECT/CT.

Yimin Liu1,2, Yonghong Dang1,2, Li Huo1,2, Ya Hu3, Ou Wang4, He Liu5, Xiaoyan Chang6, Yu Liu1,2, Xiaoping Xing4, Fang Li1,2, Quan Liao3, Marcus Hacker7, Xiang Li8, Michael C Kreissl9.   

Abstract

We aimed to assess the value of 11C-choline PET in patients with primary hyperparathyroidism and negative or discordant results on 99mTc-sestamibi imaging and neck ultrasound.
Methods: Eighty-seven such patients were assessed and subsequently underwent parathyroidectomy. PET/CT image data were analyzed semiquantitatively using SUVmax and SUV ratios (target to contralateral thyroid gland and carotid artery). A positive PET/CT result was defined as focal uptake significantly higher than regular thyroid tissue. Ectopic foci were also considered positive. Inconclusive PET/CT cases were defined as a lesion with uptake equal to normal thyroid tissue. If no prominent or ectopic uptake was detectable, the PET/CT result was considered negative.
Results: When dichotomizing the 11C-choline PET/CT imaging results by defining lesions with both positive and inconclusive uptake as positive, we found 84 of 92 lesions (91.3%) to have true-positive uptake whereas 8 lesions (8.7%) had false-positive uptake. One lesion showed false-negative uptake; the sensitivity was 98.8%. The corresponding positive predictive value for lesions was 91.3%. The mean SUVmax was 6.15 ± 4.92 in 72 lesions with positive uptake (70 patients) and 2.96 ± 2.32 in 20 lesions with inconclusive uptake (18 patients).
Conclusion: These results in a large group of patients indicate that 11C-choline PET/CT is a promising tool for parathyroid adenoma localization when ultrasound and 99mTc-sestamibi imaging yield negative or discordant results.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  11C-choline; PET/CT; primary hyperparathyroidism

Year:  2019        PMID: 31601698     DOI: 10.2967/jnumed.119.233213

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

Review 1.  Diagnostic Value of Choline PET in the Preoperative Localization of Hyperfunctioning Parathyroid Gland(s): A Comprehensive Overview.

Authors:  Cristina Ferrari; Giulia Santo; Paolo Mammucci; Antonio Rosario Pisani; Angela Sardaro; Giuseppe Rubini
Journal:  Biomedicines       Date:  2021-02-25

2.  Misleading localization by 18F-fluorocholine PET/CT in familial hypocalciuric hypercalcemia type-3: a case report.

Authors:  Noha N Mukhtar; Mohei El-Din M Abouzied; Mohammed H Alqahtani; Muhammad M Hammami
Journal:  BMC Endocr Disord       Date:  2021-01-26       Impact factor: 2.763

Review 3.  Preoperative Localization for Primary Hyperparathyroidism: A Clinical Review.

Authors:  Donovan Tay; Jeeban P Das; Randy Yeh
Journal:  Biomedicines       Date:  2021-04-06

4.  A retrospective analysis of the diagnostic performance of 11C-choline PET/CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant imaging in primary hyperparathyroidism.

Authors:  M E Noltes; S Kruijff; L Jansen; H E Westerlaan; W T Zandee; R A J O Dierckx; A H Brouwers
Journal:  EJNMMI Res       Date:  2021-03-26       Impact factor: 3.138

5.  A new concept for the production of 11C-labelled radiotracers.

Authors:  Jan Wenz; Felix Arndt; Samuel Samnick
Journal:  EJNMMI Radiopharm Chem       Date:  2022-03-28

6.  Preoperative imaging in primary hyperparathyroidism: Are 11 C-Choline PET/CT and 99m Tc-MIBI/123 Iodide subtraction SPECT/CT interchangeable or do they supplement each other?

Authors:  Julie W Christensen; Afefah Ismail; Susanne B Søndergaard; Finn N Bennedbaek; Birte Nygaard; Lars T Jensen; Waldemar Trolle; Christoffer Holst-Hahn; Bo Zerahn; Bent Kristensen; Martin Krakauer
Journal:  Clin Endocrinol (Oxf)       Date:  2022-02-21       Impact factor: 3.523

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.